HCV Diversity and Evolution During Antiviral Therapy
Author Information
Author(s): Cannon Nathan A., Donlin Maureen J., Fan Xiaofeng, Aurora Rajeev, Tavis John E.
Primary Institution: Saint Louis University School of Medicine
Hypothesis
Differences in pre-therapy viral genetic variability between nonresponders and relapsers will affect the response to antiviral therapy.
Conclusion
The study found that HCV sequences were stable during failed antiviral therapy, and genetic variability in NS2 may influence treatment outcomes.
Supporting Evidence
- Pre-therapy interpatient diversity was higher in relapsers than in nonresponders.
- Relapsers had more unique variations in NS2 than nonresponders.
- Both groups experienced a decline in quasispecies breadth during therapy.
Takeaway
This study looked at how the hepatitis C virus changes during treatment and found that some genetic differences can help predict if a patient will respond to therapy.
Methodology
The study analyzed pre- and post-therapy sequences from 20 participants, comparing genetic diversity and mutation patterns between nonresponders and relapsers.
Potential Biases
Potential bias due to the small sample size and the focus on specific genetic regions.
Limitations
The study did not address variability associated with the race of the patient due to a low number of samples.
Participant Demographics
The study included 205 Caucasian American and 196 African American participants.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website